cerebral small vessel disease (CSVD)
Conditions
Interventions
Edaravone dexborneol group:Nil
control group:None
Sponsors
The First Affiliated Hospital of Kunming Medical University
Eligibility
Sex/Gender
All
Age
18 Years to 85 Years
Inclusion criteria
Inclusion criteria: 1. Aged 18-85 years, gender is not limited; 2. Acute lacunar cerebral infarction ( Acute lacunar cerebral infarction ( NHISS score 2 points); 3. The patient has no cognitive impairment, or has mild function (CDR < 1 point).
Exclusion criteria
Exclusion criteria: 1. Have a history of familial genetic dementia; 2. Suffering from any cause of disorder of consciousness; 3. Those with severe aphasia or physical disability who cannot complete the neuropsychological examination; 4. Those who currently suffer from related depression (score of Hamilton scale>17) or mental illness; 5. Have a history of alcoholism, or drug addiction, traumatic brain injury, epilepsy, normal intracranial pressure, etc., which can cause cognitive impairment, have a history of alcoholism, or drug addiction, traumatic brain injury, epilepsy, normal intracranial pressure, etc. can cause cognitive impairment, history of alcoholism, or drug addiction, traumatic brain injury, epilepsy, normal intracranial pressure, etc. can cause cognitive impairment, history of alcoholism, or drug addiction, traumatic brain injury, epilepsy, normal intracranial pressure, etc. can cause cognitive impairment, history of alcoholism, or drug addiction, traumatic brain injury, epilepsy, normal intracranial pressure, etc. can cause cognitive impairment, history of alcoholism, or neurological diseases that can cause cognitive impairment, such as brain trauma, epilepsy, normal intracranial pressure, or drug addiction; 6. Suffering from systemic diseases that may lead to mild cognitive impairment (such as liver and kidney insufficiency, endocrine vitamin deficiency); 7. Long-term use of others that affect the safety or effectiveness of the test drug, such as antipsychotics; 8. Patients who cannot accept brain MRI; 9. Patients who are participating in other studies; 10. Pregnant patients or women of reproductive age and breastfeeding; 11. Other circumstances that the researcher considers unsuitable for participation.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Proportion of patients with Clinical Dementia Rating Scale (CDR) score <1; | — |
Secondary
| Measure | Time frame |
|---|---|
| The proportion of patients with MTx-%C>78%;Change in MMSE scale score from baseline;Change in MoCA scale score from baseline;Changes from baseline in daily living function scale (ADL) scores;Change from baseline in neuropsychiatric questionnaire (NPI);Differences in Hamilton Depression/Anxiety Scale Scores (HAMD/HAMA);Changes of serological inflammatory markers compared with baseline values and differences between groups;Change from baseline in CSVD overall load score;Default subgroup analysis; | — |
Countries
China
Contacts
Public ContactLiu Xiaolei
Outcome results
None listed